Thiamylal: Difference between revisions
Jump to navigation
Jump to search
m (Robot: Automated text replacement (-{{reflist}} +{{reflist|2}}, -<references /> +{{reflist|2}}, -{{WikiDoc Cardiology Network Infobox}} +)) |
No edit summary |
||
| Line 1: | Line 1: | ||
{{ | {{Drugbox | ||
| IUPAC_name | | verifiedrevid = 470606310 | ||
| IUPAC_name = 5-allyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1''H'',5''H'')-dione | |||
| image = ThiamylalSVG.svg | |||
| width = 100 | |||
<!--Clinical data--> | |||
| tradename = | |||
| Drugs.com = {{drugs.com|international|thiamylal}} | |||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | |||
| pregnancy_US = <!-- A / B / C / D / X --> | |||
| pregnancy_category = | |||
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | |||
| legal_CA = Schedule III | |||
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> | |||
| legal_US = Schedule III | |||
| legal_status = | |||
| routes_of_administration = | |||
<!--Pharmacokinetic data--> | |||
| bioavailability = | |||
| protein_bound = | |||
| metabolism = Hepatic | |||
| elimination_half-life = 14.3 h (cats) | |||
| excretion = | |||
<!--Identifiers--> | |||
| CASNo_Ref = {{cascite|correct|CAS}} | |||
| CAS_number_Ref = {{cascite|correct|??}} | |||
| CAS_number = 77-27-0 | |||
| ATCvet = yes | |||
| ATC_prefix = N01 | |||
| ATC_suffix = AF90 | |||
| PubChem = 3032285 | |||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | |||
| DrugBank = DB01154 | |||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | |||
| ChemSpiderID = 2297298 | |||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = 01T23W89FR | |||
| KEGG_Ref = {{keggcite|correct|kegg}} | |||
| KEGG = D06106 | |||
| ChEBI_Ref = {{ebicite|correct|EBI}} | |||
| ChEBI = 9536 | |||
| ChEMBL_Ref = {{ebicite|correct|EBI}} | |||
| ChEMBL = 440 | |||
<!--Chemical data--> | |||
| C=12 | H=18 | N=2 | O=2 | S=1 | |||
| molecular_weight = 254.35 g/mol | |||
| smiles = O=C1NC(=S)NC(=O)C1(C(C)CCC)C\C=C | |||
| InChI = 1/C12H18N2O2S/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17) | |||
| InChIKey = XLOMZPUITCYLMJ-UHFFFAOYAG | |||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChI = 1S/C12H18N2O2S/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17) | |||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChIKey = XLOMZPUITCYLMJ-UHFFFAOYSA-N | |||
| synonyms = Thiamylal, Thioseconal, Surital | | synonyms = Thiamylal, Thioseconal, Surital | ||
}} | }} | ||
'''Thiamylal''' (Surital) is a [[barbiturate]] derivative invented in the 1950s. It has [[sedative]], [[anticonvulsant]] and [[hypnotic]] effects, and is used as a strong but short acting sedative. | '''Thiamylal''' ('''Surital''') is a [[barbiturate]] derivative invented in the 1950s. It has [[sedative]], [[anticonvulsant]], and [[hypnotic]] effects, and is used as a strong but short acting sedative. Thiamylal is still in current use, primarily for induction in [[surgical]] [[anaesthesia]] <ref> Hsieh MY, Hung GY, Hsieh YL, Chang CY, Hwang B. Deep sedation with methohexital or thiamylal with midazolam for invasive procedures in children with acute lymphoblastic leukemia. Acta Paediatrica Taiwan. 2005 Sep-Oct;46(5):294-300. </ref> or as an anticonvulsant to counteract side effects from other anaesthetics.<ref> Tsai CJ, Wang HM, Lu IC, Tai CF, Wang LF, Soo LY, Lu DV. Seizure after local anesthesia for nasopharyngeal angiofibroma. Kaohsiung Journal of Medical Sciences. 2007 Feb;23(2):97-100. </ref> It is the thiobarbiturate analogue of [[secobarbital]]. | ||
== References == | == References == | ||
<references /> | |||
{{ | {{Sedatives}} | ||
{{GABAAR PAMs}} | |||
[[Category:Thiobarbiturates]] | [[Category:Thiobarbiturates]] | ||
[[Category: | [[Category:GABAA receptor positive allosteric modulators]] | ||
{{ | {{nervous-system-drug-stub}} | ||
Revision as of 20:28, 10 April 2015
| File:ThiamylalSVG.svg | |
| Clinical data | |
|---|---|
| Synonyms | Thiamylal, Thioseconal, Surital |
| AHFS/Drugs.com | International Drug Names |
| ATCvet code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Elimination half-life | 14.3 h (cats) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C12H18N2O2S |
| Molar mass | 254.35 g/mol |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Thiamylal (Surital) is a barbiturate derivative invented in the 1950s. It has sedative, anticonvulsant, and hypnotic effects, and is used as a strong but short acting sedative. Thiamylal is still in current use, primarily for induction in surgical anaesthesia [1] or as an anticonvulsant to counteract side effects from other anaesthetics.[2] It is the thiobarbiturate analogue of secobarbital.
References
- ↑ Hsieh MY, Hung GY, Hsieh YL, Chang CY, Hwang B. Deep sedation with methohexital or thiamylal with midazolam for invasive procedures in children with acute lymphoblastic leukemia. Acta Paediatrica Taiwan. 2005 Sep-Oct;46(5):294-300.
- ↑ Tsai CJ, Wang HM, Lu IC, Tai CF, Wang LF, Soo LY, Lu DV. Seizure after local anesthesia for nasopharyngeal angiofibroma. Kaohsiung Journal of Medical Sciences. 2007 Feb;23(2):97-100.